Neuromuscular Blockade Therapeutics
1. Bridion patent expiration
Treatment: Reversal of neuromuscular blockage induced by rocuronium bromide or vecuronium bromide; Reversal of drug-induced neuromuscular block
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44733 | MSD SUB MERCK | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
Jan, 2026
(18 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6949527 | MSD SUB MERCK | 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
Jan, 2021
(4 years ago) | |
| US7265099 | MSD SUB MERCK | Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
Aug, 2020
(5 years ago) | |
| US7265009 | MSD SUB MERCK | HDP-CVD methodology for forming PMD layer |
Aug, 2020
(5 years ago) | |
|
USRE44733 (Pediatric) | MSD SUB MERCK | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
Jul, 2026
(6 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2020 |
| M(M-262) | Jun 09, 2023 |
| M(M-291) | Jan 22, 2024 |
| New Patient Population(NPP) | Dec 12, 2027 |
| Pediatric Exclusivity(PED) | Jun 12, 2028 |
Drugs and Companies using SUGAMMADEX SODIUM ingredient
NCE-1 date: 13 June, 2027
Market Authorisation Date: 15 December, 2015
Dosage: SOLUTION
How can I launch a generic of BRIDION before it's drug patent expiration?
More Information on Dosage
BRIDION family patents
2. Raplon patent expiration
Treatment: NA
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5418226 | ORGANON USA INC | Monoquaternary 2,16-bispiperidinylandrostane derivatives |
Apr, 2013
(12 years ago) | |
Drugs and Companies using RAPACURONIUM BROMIDE ingredient
Market Authorisation Date: 18 August, 1999
Dosage: INJECTABLE
More Information on Dosage
RAPLON family patents